China A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’ stock plunge, and BeiGene’s USD 1.33 billion CDK2 inhibitor deal with Ensem Therapeutics. Bristol Myers to pay $800 million…
Belgium Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines. Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively…
Belgium Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some of the key trends at play in the Belgian generics market, and his hopes for how a more sustainable healthcare…
UAE Newly promoted to manage Aspen’s Middle East and Europe region, Daniel Vella Friggieri outlines the rationale behind the company’s strategic reconfiguration, how the South-Africa headquartered firm is looking to expand its portfolio in the region via partnerships, and the importance of flexibility and out-of-the-box thinking in driving growth. The…
India Top stories from Indian pharma including Dr Reddy’s move to US online platforms, Aspen/Serum Institute’s vaccine deal for Africa, Aurobindo’s USD 37.7 million investment in subsidiary CuraTeQ and Biocon’s FDA troubles. Indian pharma market growth in August 12.1 percent (The Economic Times India) According to a study from the…
Saudi Arabia Aspen’s regional CEO for the Middle East, North Africa & Turkey, Daniel Vella Friggieri, provides insights into how the South African company’s federated model and decentralized management system translates into differentiated portfolios across regions and significant networks of local CMO partners. After more than five years with Aspen in the…
South Africa A roundup of the latest news from South African pharma, including Aspen’s impressive annual growth, Adcock Ingram’s full year profit drop, and Entos Pharma’s approval for Phase II clinical rials in South Africa for its COVID-19 DNA vaccine candidate. In addition, an African Union envoy says that vaccines made in…
Switzerland Aspen’s European Head Thomas Kerscher explains how the sale of the company’s thrombosis portfolio to Mylan has led to an organisational transformation in Europe with a leaner approach and an exclusive focus on anaesthesia. Kerscher also outlines the South African company’s response to the COVID-19 pandemic amid skyrocketing demand for…
South Africa With Africa struggling to vaccinate its populations against COVID-19, the World Bank – along with government institutions from the USA, Germany, and France – has intervened to loan South African firm Aspen Pharmacare EUR 600 million (USD 712 million) with the aim of increasing vaccine manufacturing know how across the…
South Africa The latest from South African pharma, including President Ramaphosa’s blunt criticism of Big Pharma, Aspen’s reception of USD 700 million in international financial aid, Adcock Ingram’s disappointing results as fewer elective surgeries and doctor visits hit their first half revenue, and the battle to bridge digital divide in COVID-19 vaccination…
South Africa South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S, boosting the company’s share price as well as its global profile. Aspen is best known internationally for bringing generic antiretrovirals for HIV to…
Spain The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia business have been critical milestones for the maverick South African pharmaceutical outfit Aspen, enabling the company to establish a consolidated presence across Europe, including the opening of the firm’s first-ever Spanish affiliate only two and a half…
See our Cookie Privacy Policy Here